First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution
Advanced breast cancer is an incurable disease, with a median overall survival of 3 years, including in countries without access problems. Although chemotherapy is reserved in some cases, it is still used in many countries as a first-line therapy. The aim of our study is to evaluate the first-line t...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/12/581 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850241129682829312 |
|---|---|
| author | Guillermo Valencia Patricia Rioja Miguel Chirito Olenka Peralta Jorge Sánchez Connie Rabanal Raúl Mantilla Zaida Morante Hugo Fuentes Carlos Castaneda Tatiana Vidaurre Cristian Pacheco Silvia Neciosup Henry L. Gomez |
| author_facet | Guillermo Valencia Patricia Rioja Miguel Chirito Olenka Peralta Jorge Sánchez Connie Rabanal Raúl Mantilla Zaida Morante Hugo Fuentes Carlos Castaneda Tatiana Vidaurre Cristian Pacheco Silvia Neciosup Henry L. Gomez |
| author_sort | Guillermo Valencia |
| collection | DOAJ |
| description | Advanced breast cancer is an incurable disease, with a median overall survival of 3 years, including in countries without access problems. Although chemotherapy is reserved in some cases, it is still used in many countries as a first-line therapy. The aim of our study is to evaluate the first-line treatment choices and the factors that influence therapeutic decisions. A retrospective analysis was conducted of hormone receptor (+)/HER2 (−) advanced breast cancer patients classified into three groups according to the first-line and second-line treatment received: endocrine therapy–chemotherapy, endocrine therapy–endocrine therapy and chemotherapy–endocrine therapy. Additionally, we explored the overall survival of sequencing therapy groups. First-line chemotherapy was chosen in 34% of patients. Also, around 60% of our patients met the “aggressive disease” criteria from the RIGHT Choice trial, justifying the use of chemotherapy in a population with poor prognosis. Furthermore, de novo and progressive disease were prognostic factors that influenced the use of chemotherapy as a first-line treatment. Regarding overall survival, the sequencing treatment groups in this trial saw an increase in survival compared with patients of the MONALEESA trials (endocrine therapy alone arms). No significant differences in progression-free survival or overall survival were found in the treatment sequencing groups. There was a higher use of chemotherapy as a first-line therapy, with de novo and “aggressive disease” criteria being the main factors to influence the decision. |
| format | Article |
| id | doaj-art-b08e046f76fe4b2bbcf315fa0b40b897 |
| institution | OA Journals |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-b08e046f76fe4b2bbcf315fa0b40b8972025-08-20T02:00:41ZengMDPI AGCurrent Oncology1198-00521718-77292024-12-0131127890790210.3390/curroncol31120581First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public InstitutionGuillermo Valencia0Patricia Rioja1Miguel Chirito2Olenka Peralta3Jorge Sánchez4Connie Rabanal5Raúl Mantilla6Zaida Morante7Hugo Fuentes8Carlos Castaneda9Tatiana Vidaurre10Cristian Pacheco11Silvia Neciosup12Henry L. Gomez13Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima 15036, PeruDepartment of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima 15036, PeruDepartment of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima 15036, PeruDepartment of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima 15036, PeruDepartment of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima 15036, PeruDepartment of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima 15036, PeruFaculty of Natural Sciences and Mathematics, Universidad Nacional Federico Villareal, Lima 15001, PeruDepartment of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima 15036, PeruDepartment of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima 15036, PeruDepartment of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima 15036, PeruDepartment of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima 15036, PeruDepartment of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima 15036, PeruDepartment of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima 15036, PeruGrupo de Estudios Clínicos Oncológicos del Perú (GECOPERU), Lima 15038, PeruAdvanced breast cancer is an incurable disease, with a median overall survival of 3 years, including in countries without access problems. Although chemotherapy is reserved in some cases, it is still used in many countries as a first-line therapy. The aim of our study is to evaluate the first-line treatment choices and the factors that influence therapeutic decisions. A retrospective analysis was conducted of hormone receptor (+)/HER2 (−) advanced breast cancer patients classified into three groups according to the first-line and second-line treatment received: endocrine therapy–chemotherapy, endocrine therapy–endocrine therapy and chemotherapy–endocrine therapy. Additionally, we explored the overall survival of sequencing therapy groups. First-line chemotherapy was chosen in 34% of patients. Also, around 60% of our patients met the “aggressive disease” criteria from the RIGHT Choice trial, justifying the use of chemotherapy in a population with poor prognosis. Furthermore, de novo and progressive disease were prognostic factors that influenced the use of chemotherapy as a first-line treatment. Regarding overall survival, the sequencing treatment groups in this trial saw an increase in survival compared with patients of the MONALEESA trials (endocrine therapy alone arms). No significant differences in progression-free survival or overall survival were found in the treatment sequencing groups. There was a higher use of chemotherapy as a first-line therapy, with de novo and “aggressive disease” criteria being the main factors to influence the decision.https://www.mdpi.com/1718-7729/31/12/581advanced breast cancerHR positive/HER2 negativechemotherapyendocrine therapyoverall survivalsequencing treatment |
| spellingShingle | Guillermo Valencia Patricia Rioja Miguel Chirito Olenka Peralta Jorge Sánchez Connie Rabanal Raúl Mantilla Zaida Morante Hugo Fuentes Carlos Castaneda Tatiana Vidaurre Cristian Pacheco Silvia Neciosup Henry L. Gomez First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution Current Oncology advanced breast cancer HR positive/HER2 negative chemotherapy endocrine therapy overall survival sequencing treatment |
| title | First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution |
| title_full | First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution |
| title_fullStr | First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution |
| title_full_unstemmed | First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution |
| title_short | First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution |
| title_sort | first line 1l treatment decision patterns and survival of hormone receptor hr positive her2 negative advanced breast cancer abc patients in a latin american latam public institution |
| topic | advanced breast cancer HR positive/HER2 negative chemotherapy endocrine therapy overall survival sequencing treatment |
| url | https://www.mdpi.com/1718-7729/31/12/581 |
| work_keys_str_mv | AT guillermovalencia firstline1ltreatmentdecisionpatternsandsurvivalofhormonereceptorhrpositiveher2negativeadvancedbreastcancerabcpatientsinalatinamericanlatampublicinstitution AT patriciarioja firstline1ltreatmentdecisionpatternsandsurvivalofhormonereceptorhrpositiveher2negativeadvancedbreastcancerabcpatientsinalatinamericanlatampublicinstitution AT miguelchirito firstline1ltreatmentdecisionpatternsandsurvivalofhormonereceptorhrpositiveher2negativeadvancedbreastcancerabcpatientsinalatinamericanlatampublicinstitution AT olenkaperalta firstline1ltreatmentdecisionpatternsandsurvivalofhormonereceptorhrpositiveher2negativeadvancedbreastcancerabcpatientsinalatinamericanlatampublicinstitution AT jorgesanchez firstline1ltreatmentdecisionpatternsandsurvivalofhormonereceptorhrpositiveher2negativeadvancedbreastcancerabcpatientsinalatinamericanlatampublicinstitution AT connierabanal firstline1ltreatmentdecisionpatternsandsurvivalofhormonereceptorhrpositiveher2negativeadvancedbreastcancerabcpatientsinalatinamericanlatampublicinstitution AT raulmantilla firstline1ltreatmentdecisionpatternsandsurvivalofhormonereceptorhrpositiveher2negativeadvancedbreastcancerabcpatientsinalatinamericanlatampublicinstitution AT zaidamorante firstline1ltreatmentdecisionpatternsandsurvivalofhormonereceptorhrpositiveher2negativeadvancedbreastcancerabcpatientsinalatinamericanlatampublicinstitution AT hugofuentes firstline1ltreatmentdecisionpatternsandsurvivalofhormonereceptorhrpositiveher2negativeadvancedbreastcancerabcpatientsinalatinamericanlatampublicinstitution AT carloscastaneda firstline1ltreatmentdecisionpatternsandsurvivalofhormonereceptorhrpositiveher2negativeadvancedbreastcancerabcpatientsinalatinamericanlatampublicinstitution AT tatianavidaurre firstline1ltreatmentdecisionpatternsandsurvivalofhormonereceptorhrpositiveher2negativeadvancedbreastcancerabcpatientsinalatinamericanlatampublicinstitution AT cristianpacheco firstline1ltreatmentdecisionpatternsandsurvivalofhormonereceptorhrpositiveher2negativeadvancedbreastcancerabcpatientsinalatinamericanlatampublicinstitution AT silvianeciosup firstline1ltreatmentdecisionpatternsandsurvivalofhormonereceptorhrpositiveher2negativeadvancedbreastcancerabcpatientsinalatinamericanlatampublicinstitution AT henrylgomez firstline1ltreatmentdecisionpatternsandsurvivalofhormonereceptorhrpositiveher2negativeadvancedbreastcancerabcpatientsinalatinamericanlatampublicinstitution |